Our results indicate that systemic treatment with combinations including pan-Bcl-2 or Bcl-xL-specific inhibitors (e.g., ABT-263 and A-1155463) could be harmful for cancer patients (similarly to round worms), because patients are constantly exposed to radiation, chemicals, and viral infections. This evidence concerns the gene BCL2L1 and cancer.